Tumor burden is predictive of survival in patients with non–small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib

JH Park, TM Kim, B Keam, YK Jeon, SH Lee, DW Kim… - Clinical lung cancer, 2013 - Elsevier
Background Although activating epidermal growth factor receptor (EGFR) mutations are
excellent predictors of gefitinib outcome in non–small-cell lung cancer (NSCLC), most …
被引用次数：67 相关文章

Tumor Burden is Predictive of Survival in Patients With Non-Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive …

JH Park, TM Kim, B Keam, YK Jeon… - Clinical Lung …, 2013 - search.ebscohost.com
Tumor burden at baseline is predictive of inferior survival in patients with non-small-cell lung
cancer and who harbor activating epidermal growth factor receptor (EGFR) mutations and …

[引用][C] Tumor Burden is Predictive of Survival in Patients With Non–Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who …

JH Park, TM Kim, B Keam, YK Jeon, SH Lee… - Clinical Lung …, 2013 - cir.nii.ac.jp
Tumor Burden is Predictive of Survival in Patients With Non–Small-Cell Lung Cancer and With
Activating Epidermal Growth Factor Receptor Mutations Who Receive Gefitinib | CiNii Research …

Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib

JH Park, TM Kim, B Keam, YK Jeon… - Clinical Lung …, 2013 - snucm.elsevierpure.com
Background: Although activating epidermal growth factor receptor (EGFR) mutations are
excellent predictors of gefitinib outcome in non-small-cell lung cancer (NSCLC), most …

Tumor Burden is Predictive of Survival in Patients With Non-Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive …

JH Park, TM Kim, B Keam, YK Jeon, SH Lee… - Clinical Lung …, 2013 - s-space.snu.ac.kr
Tumor burden at baseline is predictive of inferior survival in patients with non-small-cell lung
cancer and who harbor activating epidermal growth factor receptor (EGFR) mutations and …

Tumor Burden is Predictive of Survival in Patients With Non–Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive …

JH Park, TM Kim, B Keam, YK Jeon… - Clinical Lung …, 2013 - clinical-lung-cancer.com
Background Although activating epidermal growth factor receptor (EGFR) mutations are
excellent predictors of gefitinib outcome in non–small-cell lung cancer (NSCLC), most …

Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib.

JH Park, TM Kim, B Keam, YK Jeon, SH Lee… - Clinical Lung …, 2013 - europepmc.org
Background Although activating epidermal growth factor receptor (EGFR) mutations are
excellent predictors of gefitinib outcome in non-small-cell lung cancer (NSCLC), most …

Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib

JH Park, TM Kim, B Keam, YK Jeon… - Clinical lung …, 2013 - pubmed.ncbi.nlm.nih.gov
Background Although activating epidermal growth factor receptor (EGFR) mutations are
excellent predictors of gefitinib outcome in non-small-cell lung cancer (NSCLC), most …

Tumor Burden is Predictive of Survival in Patients With Non–Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive …

JH Park, TM Kim, B Keam, YK Jeon, SH Lee… - Clinical Lung …, 2013 - infona.pl
Although activating epidermal growth factor receptor (EGFR) mutations are excellent
predictors of gefitinib outcome in non–small-cell lung cancer (NSCLC), most patients …